FDA Issues Final Guidances on Postmarket Surveillance and Post-approval Studies

This month, the FDA issued two final guidances related to post-approval studies and postmarket surveillance of medical devices.

Per the FDA announcement, these guidances are “intended to enhance patient safety by facilitating timely initiation and completion of post-approval studies (PAS) and postmarket surveillance under section 522 of the Federal Food, Drug, and Cosmetic Act (FD&C Act). These guidances are also intended to increase transparency to stakeholders on the FDA’s approach to the issuance and tracking of 522 orders and PAS requirements.”

Procedures for Handling Post-Approval Studies Imposed by Premarket Approval Application Orderincludes:

The final guidance replaces the guidance issued in June 2009.

Postmarket Surveillance Under Section 522 of the Federal Food, Drug, and Cosmetic Act supersedes previous guidance issued on May 16, 2016, and pertains to manufacturers of certain class II or class III devices. The final guidance covers:

 

Related Articles

About The Author

Exit mobile version